Mirum Pharmaceuticals, Inc.
General ticker "MIRM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.4B (TTM average)
Mirum Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 48.0%.
Estimated limits based on current volatility of 1.5%: low 96.63$, high 99.98$
Factors to consider:
- Total employees count: 372 (+15.5%) as of 2025
- US accounted for 81.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Commercialization challenges, Market competition, Operational and conduct risks, Manufacturing disruptions, Regulatory and compliance
- Current price 29.0% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [40.39$, 77.40$]
- 2026-12-31 to 2027-12-31 estimated range: [34.57$, 68.52$]
Financial Metrics affecting the MIRM estimates:
- Negative: with PPE of -166.4 at the end of fiscal year the price was very high
- Positive: -4.23 < Operating profit margin, % of -4.07
- Positive: Investing cash flow per share per price, % of -0.60 > -0.64
- Positive: -3.10 < Return on assets ratio (scaled to [-100,100]) of -2.70
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: 0.28 < Operating cash flow per share per price, % of 1.39
- Positive: Inventory ratio change, % of -1.68 <= -0.75
- Positive: Interest expense per share per price, % of 0.36 <= 0.75
- Positive: 18.97 < Shareholder equity ratio, % of 37.34 <= 42.26
Short-term MIRM quotes
Long-term MIRM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $186.37MM | $336.89MM | $521.31MM |
| Operating Expenses | $295.53MM | $424.49MM | $543.45MM |
| Operating Income | $-109.15MM | $-87.61MM | $-22.14MM |
| Non-Operating Income | $-53.27MM | $0.69MM | $0.71MM |
| Interest Expense | $15.11MM | $14.31MM | $14.39MM |
| R&D Expense | $102.61MM | $140.63MM | $186.18MM |
| Income(Loss) | $-162.42MM | $-86.91MM | $-21.43MM |
| Taxes | $0.99MM | $1.03MM | $1.94MM |
| Net Income(Loss)* | $-163.41MM | $-87.94MM | $-23.36MM |
| Stockholders Equity | $248.67MM | $225.64MM | $314.69MM |
| Inventory | $22.31MM | $22.40MM | $24.89MM |
| Assets | $646.62MM | $670.75MM | $842.81MM |
| Operating Cash Flow | $-70.94MM | $10.32MM | $55.83MM |
| Capital expenditure | $20.11MM | $0.99MM | $0.95MM |
| Investing Cash Flow | $-107.20MM | $-90.12MM | $-23.95MM |
| Financing Cash Flow | $336.60MM | $17.70MM | $40.14MM |
| Earnings Per Share** | $-4.00 | $-1.85 | $-0.47 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.